Burrage Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Burrage Capital Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-88,445	Closed	-$1.19M	–	34
2020 Q1	$1.19M	Sell	88,445 -99,531	-53%	-$1.89M	1.17%	25
2019 Q4	$4.54M	Buy	+187,976	New	+$3.89M	3.04%	14

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Burrage Capital Management's AERI Position: Q2 2020 in Review

Burrage Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q2 2020, closing a stake of 88,445 shares — an estimated $1.19M sold.

Burrage Capital Management first reported a position in AERI in Q4 2019 and held it in 2 quarters. The position peaked at $4.54M in Q4 2019. 155 funds tracked by Wall St. Rank hold AERI as of Q2 2020.

Burrage Capital Management reported no remaining Aerie Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Burrage Capital Management sold 88,445 Aerie Pharmaceuticals shares in Q2 2020, an estimated $1.19M.
Burrage Capital Management first reported a position in Aerie Pharmaceuticals in Q4 2019 and held it in 2 quarters.
Burrage Capital Management's Aerie Pharmaceuticals position peaked at $4.54M in Q4 2019.
155 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2020.

Based on Burrage Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.